Fatigue, anemia, nausea and neutropenia together with a risk of myelodysplastic syndrome/acute myeloid leukemia accompany the use of synthetic PARP1/2 inhibitors (Walsh, 2018). The gene discussed is PARP1; the disease is Decreased total neutrophil count.